自CRISPR技术首次问世以来，已逾十年，其对生命科学与生物医学研究领域的变革性影响不容小觑。该技术显著缩短了动物模型的构建周期，为多物种新模型的开发提供了前所未有的机遇，加速并拓宽了筛选策略的应用范围，尤为重要的是，促进了针对先前难以治愈的遗传性疾 ...

Research analysts at William Blair issued their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Monday, December 9th. William Blair analyst S. Corwin ...

Cells in the immune system don't always fight; they often rest and wait for threats, like viruses or bacteria.

A research team have recently published their article, "Rationally designed pooled CRISPRi-seq uncovers an inhibitor of ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated ...

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

In a new study published in Nature, scientists from Gladstone Institutes and UC San Francisco (UCSF) focused on T cells and ...

Toxoplasma gondii parasites can use secreted factors to compensate for genetic defects in neighbouring parasites, highlighting a limitation of pooled CRISPR screens.

Researchers from the University of Illinois have reported complementary discoveries that will improve scientists' ...